PMC8130701_01
Hybrid magnetic resonance-positron emission tomography imaging at the initial presentation 8 months after completion of the chemoradiotherapy. (a) Contrast-enhanced magnetic resonance imaging showing evidence of patchy areas of enhancement (black arrow) adjacent to the postoperative cavity (white arrow). (b) F-18 flourodeoxyglucose positron emission tomography image showing intense gyral uptake in the left parietal lobe (white arrow). Note that the uptake on F-18 flourodeoxyglucose is not corresponding to the areas of contrast enhancement
IJNM-36-53-g001.jpg
PMC8130701_01_IJNM-36-53-g001.jpg
F1
MRI showed evidence of T2/fluid-attenuated inversion recovery (FLAIR) hyperintense signal conforming to the gyri in the left parietal lobe, and postcontrast T1 images showed few patchy focal areas of postcontrast enhancement [Figure 1a]. On PET images, intense tracer uptake was noted along the gyri only in the areas corresponding to hyperintensity, and there was no tracer uptake in the foci which showed postcontrast enhancement [Figure 1b] or the cortex surrounding the postoperative cavity.
Tc-99m glucohepatonate single-photon emission computed tomography done after 1 week of magnetic resonance-positron emission tomography. Single-photon emission computed tomography image (a) and fused single-photon emission computed tomography/ computed tomography (b) acquired post-Tc-99m glucohepatonate injection showing uptake corresponding to the areas of enhancement on magnetic resonance imaging (white arrow in a and black arrow in b). Note that the areas of gyral uptake seen on positron emission tomography images are no longer appreciated
IJNM-36-53-g002.jpg
PMC8130701_01_IJNM-36-53-g002.jpg
F2
Early 1 h and delayed 3 h images showed focal abnormal increase in tracer uptake corresponding to areas of contrast enhancement on MRI, which in turn corresponded to the site of the primary lesion [Figure 2].